Cabilly patent overturned; FDA wants new Xolair warning; Avastin sales threatened.
|
U.S. researchers find clues that could one day help predict which women should pass on breast cancer drug Herceptin.
|
U.S. Presidential candidate proposes legislation that would help bring generic versions of biotech drugs to market.
|
For the second year in a row, deaths from dread disease drop—but new treatments are only part of the story.
|
Tanox shareholders approve the acquisition by Genentech.
|
Strong sales of cancer, eye treatments help biotech giant beat analyst expectations by a nickel.
|
Drug developer scores deal worth $40M for work on cancer-fighting drugs.
|
Biotech combination will expand sales of Xolair asthma drug.
|
New price caps still leave cancer treatment beyond reach of most.
|
Concerns about cancer drugs overshadow successful drug launch, strong earnings, guidance.
|
The Merck subsidiary has yeast that can copy human cell chemistry.
|
Roche puts brakes on Avastin trial; Barr buys PLIVA for $2.2B; Cyberonics gets a subpoena.
|
Traditionally the home turf of biotech companies, big pharma is making strides in developing new cancer drugs.
|
The drug maker’s profits top forecasts, but the stock is dinged on disappointing sales of lymphoma drug.
|
Despite California's huge bond issue, funding is still the biggest challenge facing stem cell researchers.
|
Lymphoma drug from Genentech, Biogen, and Roche OK'd for rheumatoid arthritis.
|
Swiss drug maker files for authorization to market early-stage breast cancer treatment with European Medicines Agency.
|
VC firm will invest $900 million in IT, life sciences, clean energy, pandemic preparedness, and bio defense.
|
Pharmaceutical company giants Roche and Genentech suspend recruitment for trials of their colon cancer drug Avastin after patients die.
|
Biotech firm GlycoFi shows that yeast can improve drug function by helping control the drug’s molecular structure.
|
Page
1
of
3
|